Usana Health Sciences Lowers FY2026 Adj EPS Guidance from $1.95-$2.29 to $0.76 vs $2.12 Est; Lowers FY2026 Sales Guidance from $925.000M-$1.000B to $910.000M vs $945.097M Est
Usana Health Sciences (NYSE:USNA) lowers FY2026 Adj EPS guidance from $1.95-$2.29 to $0.76 vs $2.12 analyst estimate. Lowers FY2026 sales outlook from $925.000 million-$1.000 billion to $910.000 million vs $945.097
Usana Health Sciences said it will make much less money next year than it expected before—both from sales and profits. When a company cuts its outlook like this, it's a sign they're facing real challenges, so watch how they explain what went wrong.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.